Clinical-stage biotechnology company focused on genomic therapies for genetic diseases.
Sangamo Therapeutics, Inc. is a forward-looking clinical-stage biotechnology company specializing in the development of transformative genomic medicines. Leveraging cutting-edge platform technologies in gene therapy, cell therapy, genome editing, and genome regulation, the company is dedicated to translating scientific innovations into therapies that profoundly impact patients' lives.
At the core of Sangamo's capabilities is its zinc finger protein (ZFP) technology platform. This platform enables the creation of zinc finger nucleases, proteins essential for modifying DNA sequences by either adding or knocking out specific genes. Additionally, Sangamo develops ZFP transcription factors, proteins that play a crucial role in regulating gene expression, offering potential therapeutic avenues for a range of genetic disorders.
Sangamo's robust pipeline includes several promising canvdidates in various stages of clinical development. Among these are SB-525, currently in Phase III AFFINE clinical trials for treating hemophilia A, and ST-920, a gene therapy undergoing Phase I/II STAAR clinical trials targeting Fabry disease. The company also advances SAR445136, a cell therapy in Phase I/II PRECIZN-1 trials for sickle cell disease.
Headquartered in Brisbane, California, Sangamo Therapeutics, Inc. was established in 1995. The company operates with a collaborative approach, engaging in strategic partnerships with leading entities such as Biogen MA, Inc., Kite Pharma, Inc., Pfizer Inc., Sanofi S.A., and others. This collaborative ecosystem enhances Sangamo's research and development efforts, facilitating the advancement of innovative therapies aimed at addressing complex medical challenges.